Table 2 Recommendations for the pharmacological management of IBD after the peak of the COVID-19 pandemic (adapted from the SIGENP position paper) [16]
Topic | Recommended |
|---|---|
Steroids for induction | Yes (accelerated steroid weaning if clinically indicated) |
Suspension of immunomodulators | |
▪As monotherapy | No |
▪As combination therapy | No |
Suspension of biologics | |
▪As monotherapy | No |
▪As combination therapy | No |
Start of immunosuppressants or anti-TNF-α | Yes |
Intervals and doses of anti-TNF-α | Regular |
RT-PCR/serological screening for SARS-CoV-2 before starting anti-TNF-α therapy | No |
Vedolizumab and ustekinumab use | Yes (not contraindicated) |